TrialOrphanet journal of rare diseases2018

Safety, effectiveness, and impact on quality of life of self-administration with plasma-derived nanofiltered C1 inhibitor (Berinert®) in patients with hereditary angioedema: the SABHA study.

Andrea Zanichelli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.